AlexanderISpiraMD

Clinical Trials

• Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01

  Completed

  Phase 2

• Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11

  Terminated

  Phase 3

• A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01

  Completed

  Phase 1, Phase 2

• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01

  Completed

  Phase 1, Phase 2

• A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01

  Completed

  Phase 1

• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28

  Completed

  Phase 3

• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29

  Completed

  Phase 2

• Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14

  Completed

  Phase 2

• A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy Start of enrollment: 2012 Jan 07

  Terminated

  Phase 1, Phase 2

• MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10

  Completed

  Phase 2

• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16

  Active, not recruiting

  Phase 3

• Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Start of enrollment: 2014 Jan 01

  Completed

  Phase 1

• Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Start of enrollment: 2014 Mar 01

  Completed

  Phase 1, Phase 2

• Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16

  Terminated

  Phase 2

• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14

  Active, not recruiting

  Phase 3

• Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05

  Terminated

  Phase 1, Phase 2

• Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22

  Completed

  Phase 1

• A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Start of enrollment: 2019 Apr 01

  Active, not recruiting

  Phase 1

• Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Start of enrollment: 2020 May 28

  Active, not recruiting

  Phase 2

• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors Start of enrollment: 2020 Feb 24

  Active, not recruiting

  Phase 1, Phase 2

• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2020 Sep 29

  Active, not recruiting

  Phase 2

• PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Start of enrollment: 2020 Aug 11

  Terminated

  Phase 1, Phase 2

• Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies Start of enrollment: 2020 Oct 12

  Active, not recruiting

  Phase 1

• A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer Start of enrollment: 2022 Mar 22

  Active, not recruiting

  Phase 1

  Roles: Contact

• Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09

  Recruiting

  Phase 1, Phase 2

  Roles: Contact

• Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Start of enrollment: 2019 Sep 21

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Contact

• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer Start of enrollment: 2019 Apr 19

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• RTX-240 Monotherapy and in Combination With Pembrolizumab Start of enrollment: 2020 May 06

  Terminated

  Phase 1, Phase 2

  Roles: Contact

• ASCO Survey on COVID-19 in Oncology (ASCO) Registry Start of enrollment: 2020 Apr 19

  Active, not recruiting

  Roles: Contact

• A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 19

  Terminated

  Phase 1, Phase 2

  Roles: Contact

• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Start of enrollment: 2019 Dec 10

  Recruiting

  Phase 1

  Roles: Contact

• A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Aug 17

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator

• A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30

  Recruiting

  Phase 1, Phase 2

  Roles: Contact

• Join now to see all